help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by TAUBE, C.
Right arrow Articles by MAGNUSSEN, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by TAUBE, C.
Right arrow Articles by MAGNUSSEN, H.

Am. J. Respir. Crit. Care Med., Volume 164, Number 10, November 2001, 1810-1815

Airway Response to Inhaled Hypertonic Saline in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease

CHRISTIAN TAUBE, OLAF HOLZ, MARION MÜCKE, RUDOLF A. JÖRRES, and HELGO MAGNUSSEN

Hospital Großhansdorf, Center for Pneumology and Thoracic Surgery, Großhansdorf, Germany; and Pulmonary Research Institute, Hospital Großhansdorf, Großhansdorf, Germany

The present study aimed at delineating the mechanisms underlying the adverse response to hypertonic saline inhalation in patients with chronic obstructive pulmonary disease (COPD). Twenty patients (age, 48-70 yr; FEV1, 29-58 %pred) inhaled, on two different days in randomized order, 200 µg salbutamol from an MDI and 20 min later either 0.9% or 3% saline from an ultrasonic nebulizer for a maximum of four consecutive 5-min periods. Forced expiratory (FEV1) and inspiratory (FIV1) volumes, inspiratory capacity (IC), intrathoracic gas volume (ITGV), and specific airway resistance (SRaw) were measured. Significant changes occurred in FEV1, FIV1, IC, ITGV, and SRaw with both concentrations (p < 0.05, each) and effects were stronger with 3% as compared with 0.9% saline (p < 0.05, each). The increase in dyspnea was associated with the changes in FIV1, FEV1, IC, and ITGV, in contrast to its decrease during bronchodilation, where only FIV1 was important. Sputum analysis showed elevated concentrations of histamine after 3% as compared with 0.9% saline. These data indicate that the adverse lung function response to hypertonic saline is common in patients with moderate to severe COPD, involves both bronchoconstriction and lung hyperinflation, and could be mediated, at least partially, through activation of mast cells.




This article has been cited by other articles:


Home page
 Eur Respir JHome page
M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al.
Outcomes for COPD pharmacological trials: from lung function to biomarkers
Eur. Respir. J., February 1, 2008; 31(2): 416 - 469.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
E. Bathoorn, J. Liesker, D. Postma, G. Koeter, A. J. M. van Oosterhout, and H. A. M. Kerstjens
Safety of Sputum Induction During Exacerbations of COPD
Chest, February 1, 2007; 131(2): 432 - 438.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
H. van der Vaart, D. S. Postma, W. Timens, H. F. Kauffman, M. N. Hylkema, and N. H.T. ten Hacken
Repeated sputum inductions induce a transient neutrophilic and eosinophilic response.
Chest, October 1, 2006; 130(4): 1157 - 1164.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
S. H. Randell, R. C. Boucher, and for the University of North Carolina Virtual Lung
Effective Mucus Clearance Is Essential for Respiratory Health
Am. J. Respir. Cell Mol. Biol., July 1, 2006; 35(1): 20 - 28.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. J. Barnes, B. Chowdhury, S. A. Kharitonov, H. Magnussen, C. P. Page, D. Postma, and M. Saetta
Pulmonary Biomarkers in Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., July 1, 2006; 174(1): 6 - 14.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
S-E Dahlen and M Kumlin
Monitoring mast cell activation by prostaglandin D2 in vivo
Thorax, June 1, 2004; 59(6): 453 - 455.
[Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
C. Taube, J. A. Nick, B. Siegmund, C. Duez, K. Takeda, Y.-H. Rha, J.-W. Park, A. Joetham, K. Poch, A. Dakhama, et al.
Inhibition of Early Airway Neutrophilia Does Not Affect Development of Airway Hyperresponsiveness
Am. J. Respir. Cell Mol. Biol., June 1, 2004; 30(6): 837 - 843.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
I.E. Zuhlke, F. Kanniess, K. Richter, D. Nielsen-Gode, S. Bohme, R.A. Jorres, and H. Magnussen
Montelukast attenuates the airway response to hypertonic saline in moderate-to-severe COPD
Eur. Respir. J., December 1, 2003; 22(6): 926 - 930.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. Tobin
Compliance (COMmunicate PLease wIth Less Abbreviations, Noun Clusters, and Exclusiveness)
Am. J. Respir. Crit. Care Med., December 15, 2002; 166(12): 1534 - 1536.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. Pauwels
Inhaled Glucocorticosteroids and Chronic Obstructive Pulmonary Disease: How Full Is the Glass?
Am. J. Respir. Crit. Care Med., June 15, 2002; 165(12): 1579 - 1580.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2001
Am. J. Respir. Crit. Care Med., March 1, 2002; 165(5): 642 - 662.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2001 American Thoracic Society